InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenues | $456K-26.0% | $616K-15.8% | $731K+8083.2% | $9K |
| Cost of revenues | $54K-41.7% | $93K-39.8% | $155K+3688.2% | $4K |
| Cost of revenues - related party | $151K+6.0% | $143K-1.7% | $145K | — |
| Gross profit | $250K-34.1% | $380K-11.9% | $432K+8796.9% | $5K |
| General and administrative expenses | $3.8M+25.2% | $3.0M-9.6% | $3.3M+102.0% | $1.6M |
| Salary and benefits | $1.3M+26.7% | $1.1M+8.8% | $978K | — |
| Advertising and marketing | $823K-44.4% | $1.5M-29.5% | $2.1M+494.4% | $353K |
| Investor relations | $1.6M+244.1% | $454K-58.8% | $1.1M | — |
| Stock based compensation | $10.8M+358.3% | $2.4M+9.3% | $2.2M | — |
| Total operating expenses | $18.3M+118.9% | $8.4M-13.5% | $9.7M+383.4% | $2.0M |
| Loss from operations | -$18.0M-126.2% | -$8.0M+13.5% | -$9.2M-362.9% | -$2.0M |
| Interest expense | $104K+655.6% | $14K | — | — |
| Amortization of intangible assets | $1.1M+55.6% | $722K | — | — |
| Impairment of license agreement | $1.2M | — | — | — |
| Loss from settlement | $126K | — | — | — |
| Loss from debt extinguishment - related parties | $19K | — | — | — |
| Total other (income) expense | $2.6M+255.1% | $735K+11458.5% | -$6K-200.0% | $6K |
| Loss before income taxes | -$20.6M-137.1% | -$8.7M+5.5% | -$9.2M-361.1% | -$2.0M |
| Net loss | -$20.6M-137.1% | -$8.7M+5.5% | -$9.2M-361.1% | -$2.0M |
| Net loss attributed to non-controlling interest | -$461+57.4% | -$1K | — | — |
| Net loss attributed to Mangoceuticals, Inc. | -$20.6M-137.1% | -$8.7M+5.5% | -$9.2M-361.1% | -$2.0M |
| Basic loss per share | -$2.17+54.8% | -$4.8+44.1% | -$8.58-4415.8% | -$0.19 |
| Diluted loss per share | -$2.17+54.8% | -$4.8+44.1% | -$8.58-4415.8% | -$0.19 |
| Basic | $10.1M+408.9% | $2.0M+84.2% | $1.1M-90.1% | $10.8M |
| Diluted | $10.1M+408.9% | $2.0M+84.2% | $1.1M-90.1% | $10.8M |
| Preferred stock dividend requirements | $1.2M+46.6% | $802K | — | — |
| Net loss attributed to Mangoceuticals, Inc. common stockholders | -$21.8M-129.5% | -$9.5M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
BC-Most Active Stocks
Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study